Should OTC drugs be advertised in Russia?

19 September 2013

A debate about the legalities of advertising over the counter (OTC) drugs is waging in Eastern Europe. A report from Poland-based research and consulting company PMR says that, while the idea of introducing a ban on the advertising of OTC drugs and dietary supplements in the mass media has recently been widely discussed in Russia and Ukraine, is in unlikely than such a ban will be introduced in the near feature.

10-year discussion on advertising ban in Russia

The subject of a ban on the advertising of OTC drugs has been discussed in Russia since 2003, but its supporters have always had a strong group of opponents. The first legislative bill was put forward in 2009 but was rejected in 2010. In 2012, the State Duma (Parliament) proposed that the advertising of OTC drugs should be limited to the specialist medical press and medical events. However, in March 2013 the government opposed the introduction of such requirements. In May 2013 Veronika Skvortsova, the Health Minister, once again announced that the advertising of medicines would be banned. The Federal Antimonopoly Service opposes a ban.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical